Date & Location
Thursday, October 16, 2025, 8:00 AM - 12:00 PM Pacific Time (Online)
Friday, October 17, 2025, 8:00 AM - 12:00 PM Pacific Time (Online)
Target Audience
Specialties - Advanced Practice Nurse, Fellow/Resident, Medical Student, Nurse, Nurse Assistant, Pharmacist, Pharmacy Technician, Physician, Physician Assistant, Psychologist, Scientist / Researcher, Pharmacologist, Graduate Student, Intern, Trainee
Credits
AMA PRA Category 1 Credits™ (7.25 hours), Non-Physician Attendance (7.25 hours)
Claiming CME Credits
Upon completion of the conference, please visit: https://ucsd.cloud-cme.com/default.aspx to complete the evaluation.
Once logged into your CloudCME account, you will need to claim credit by clicking on My CME on the top right then click on Claim Credit. Enter Activity ID: 15058, complete your evaluation and then you will be able to download your certificate. Detailed instructions can be viewed here: https://bit.ly/3PXugf6.
Once you complete and submit your evaluation, your certificate will be available immediately for download. The last day to claim credit is Friday, October 31st.
Accessing Your CME Certificate
Participants are responsible for claiming CME credit through CloudCME. Certificates must be claimed within 2 weeks of the activity end date; after this period, certificates will expire. Upon completion of the evaluation, a copy of your certificate will be emailed to you. It is strongly encouraged that you download and save the certificate at that time for your records. Our office does not provide duplicate or paper copies of certificates. Your credits are always available in your transcript via CloudCME. Instructions for downloading a copy of your transcript can be found using this link.
Overview
The 2025 CMCR Symposium will highlight the very best translational, clinical, and public health research on cannabis, cannabinoids and the gut-brain axis, exploring paradoxes that have affected trust in the use of cannabinoids as therapeutics. For example, cannabinoids as a potential cause of and treatment for psychosis, or as a treatment for and cause of nausea and vomiting. The symposium will bring clarity to these apparent contradictions and promote an expansion of investigation into these important areas of research through talks by context experts and live discussion and audience Q&A.
Objectives
- Analyze the biological mechanisms of action of cannabinoids and the endocannabinoid system, and relate them to their potential therapeutic roles in conditions affecting healthy aging.
- Analyze the biological mechanisms of action of cannabinoids and the endocannabinoid system, and relate them to their potential therapeutic roles in the treatment of dementia.
- Evaluate the biological mechanisms by which cannabinoids and the endocannabinoid system function, and assess their potential impact on cancer biology.
- Critically assess research methods and apply tools and strategies to conduct rigorous clinical and translational studies on cannabinoids.
- Assess the use of cannabinoids in clinical populations and analyze their impact on public health and safety.
- Review and discuss research priorities in cannabinoid science.
- Facilitate a comprehensive research training experience for trainees, early-stage investigators, and established researchers interested in cannabis research.
- Analyze the biological mechanisms of action of cannabinoids and the endocannabinoid system, and relate them to their potential therapeutic roles in the treatment of dementia.
Course Directors and Planning Committee
David J. Grelotti, MD - Course Director, Scientific and Program Chair, 2025 CMCR Symposium
Carla Ingle and Felicia Roston - Course Coordinators / Meeting Planners
Faculty Speakers and Moderators
Click here for a list of speakers and moderators at the 2025 CMCR Symposium
Agenda
Click here to see the detailed agenda
Disclosure Statement
It is the policy of University of California San Diego School of Medicine Continuing Professional Development to ensure that the content of accredited continuing education and related materials is accurate, balanced, objective, and scientifically justified. Education must be free of the influence or control of ineligible companies, and protect learners from promotion, marketing, and commercial bias. All persons in a position to control the content of accredited continuing education must disclose all financial relationships held with ineligible companies, prior to assuming a role in the activity. Those relationships deemed relevant to the education are mitigated prior to the activity through one of the following strategies, depending on the nature of relationship and the role of the person: 1) divesting the financial relationship, 2) altering the individual’s control over content, and/or 3) validating the planning decisions and/or content through independent peer review. All relevant financial relationships are mitigated prior to the activity and mitigation strategies and necessary steps for implementation are communicated to individuals prior to them assuming their role in the activity. Persons who refuse or fail to disclose are disqualified from participating in the activity. Activities are evaluated by participants and peer reviewers to determine if the content was free of bias and met acceptable scientific standards. This information is considered in future activity planning. All relevant financial relationships and the nature of those relationships are noted below. All relevant financial relationships have been mitigated.
| Faculty Member Name | Role in Activity | Name of Ineligible Company(ies)/Nature of Relationship(s) |
| Sagnik Bhattacharyya |
Faculty |
Grant or research support-NW PharmaTech Ltd |
| Deepak D’Souza |
Faculty |
Advisor-Jazz Pharmaceuticals, Inc.|Consulting Fee-BioHaven |
| Margaret Haney |
Faculty |
Stocks or stock options, excluding diversified mutual funds-Pleo Pharma |
| Daniele Piomelli |
Faculty |
Employment-Exxel Pharma|Consulting Fee-Gencor Pacific |
| Michael Camilleri | Faculty | Stocks or stock options, excluding diversified mutual funds-Dignify Therapeutics|Stocks or stock options, excluding diversified mutual funds-Phenomix|Grant or research support-Biocodex|Grant or research support-Pfizer (Any division)|Consulting Fee-Alfasigma|Consulting Fee-Amylyx Pharmaceuticals|Consulting Fee-BioKier|Grant or research support-Brightseed Bio|Consulting Fee-Coloplast|Consulting Fee-Cumberland Pharma|Consulting Fee-Kallyope|Consulting Fee-Medpace|Consulting Fee-Monteresearch S.r.L.|Consulting Fee-McDermott Will & Emery LLP for Vanda Pharmaceuticals|Consulting Fee-Lilly (Any division)|Consulting Fee-Aclipse|Consulting Fee-Mirum Pharmaceuticals|Consulting Fee-Johnson & Johnson |
Persons in control of content of this educational activity who are not specifically identified by name above, such as (but not limited to) course directors, faculty, CPD staff, planners, editorial staff, peer reviewers, and CPD committee reviewers do not have any relevant financial relationships.
This educational activity may contain discussion of unlabeled and/or investigational uses of agents that are not approved by the FDA. Please consult the prescribing information for each product. The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California San Diego School of Medicine.
Accreditation
The University of California San Diego School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of California San Diego School of Medicine designates this Enduring Material activity for a maximum of 7.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Cultural & Linguistic Competency and Implicit Bias
Continuing medical education (CME) providers are required by state Assembly Bills 1195 and 241, and the standards created by the California Medical Association (CMA), to include components that address cultural and linguistic competency and implicit bias in CME activities. The planners and presenters of this activity has been asked to provide meaningful consideration of these standards in the selection and presentation of content. Additional information and resources are available on the UC San Diego CME website.
UC San Diego’s Commitment to Excellence and Value in Medical Education
We are dedicated to providing the highest quality educational experiences, while being mindful of our environmental and financial responsibilities. As a leader in medical education, we strive to balance excellence with fiscal stewardship, ensuring that our events are both informative and sustainable. Although this event may not be directly governed by university funding sources, we have made a conscious effort to adhere to the spirit of their guidelines and responsible spending, while delivering a high-quality experience for our attendees. We appreciate your participation and look forward to sharing knowledge and expertise with you.
Direct Commercial Support Acknowledgement
We would like to thank the following companies for providing educational support of this activity:
Jazz Pharmaceuticals
